NewGenIvf Group Limited (NASDAQ:NIVF) Stock Short Interest Rises 324.1%

NewGenIvf Group Limited (NASDAQ:NIVF) was the target of a large increase in short interest in September. As of September 30th, there was short interest totaling 70,041 shares, an increase of 324.1% from the September 15th total of 16,516 shares. Currently, 4.9% of the company’s stock are short sold. Based on an average daily volume of 84,296,451 shares, the days-to-cover ratio is presently 0.0 days.

Insider Buying and Selling at NewGenIvf Group

In other news, Director Kong Yiu Cheung acquired 625,000 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was bought at an average cost of $4.00 per share, for a total transaction of $2,500,000.00. Following the acquisition, the director directly owned 930,555 shares in the company, valued at approximately $3,722,220. The trade was a 204.55% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 31.80% of the stock is owned by company insiders.

NewGenIvf Group Price Performance

NIVF opened at $0.24 on Tuesday. The firm has a 50-day simple moving average of $4.14 and a two-hundred day simple moving average of $26.84. NewGenIvf Group has a 52 week low of $0.21 and a 52 week high of $6,156.00.

NewGenIvf Group (NASDAQ:NIVF) last released its quarterly earnings data on Wednesday, October 7th. The company reported ($53.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $72.72 by ($126.00). The business had revenue of $0.96 million during the quarter, compared to analyst estimates of $20.10 million. As a group, equities research analysts anticipate that NewGenIvf Group will post 42.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Weiss Ratings restated a “sell (d)” rating on shares of NewGenIvf Group in a research note on Friday, July 24th. Wall Street Zen raised NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, NewGenIvf Group currently has a consensus rating of “Sell”.

About NewGenIvf Group

NewGenIvf Group Limited is a reproductive-healthcare company focused on fertility treatment and assisted reproductive technology. Through its operating businesses, the company provides services intended to help individuals and couples pursue pregnancy, including in vitro fertilization (IVF) and related fertility-care procedures.

Its services may include fertility consultations, laboratory-based embryo procedures, intracytoplasmic sperm injection (ICSI), embryo transfer, fertility preservation, and genetic testing or screening associated with assisted reproduction.